Evidence map›Paper›PMID 27815945›Full record

ArticleeLife2016

A transmission-virulence evolutionary trade-off explains attenuation of HIV-1 in Uganda.

François Blanquart, Mary Kate Grabowski, Joshua Herbeck, Fred Nalugoda, David Serwadda, Michael A Eller, Merlin L Robb, Ronald Gray, Godfrey Kigozi, Oliver Laeyendecker and 6 more

Abstract read
In one paragraph

Article in eLife, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Coevolution of Age-Structured Tolerance and Virulence.Bulletin of mathematical biology · 2024
    Article
  10. Review
  11. HIV-1 subtypes maintain distinctive physicochemical signatures in Nef domains associated with immunoregulation.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2023
    Article
  12. Article
  13. Review
  14. Article
  15. Viral proteases as therapeutic targets.Molecular aspects of medicine · 2022
    Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

François BlanquartMRC Centre for Outbreak Analysis and Modelling, Imperial College London, London, United Kingdom.ORCID 0000-0003-0591-2466
Mary Kate GrabowskiDepartment of Epidemiology, Johns Hopkins University, Baltimore, United States.
Joshua HerbeckInternational Clinical Research Center, University of Washington, Seattle, United States.ORCID 0000-0003-4577-7406
Fred NalugodaRakai Health Sciences Program, Entebbe, Uganda.
David SerwaddaRakai Health Sciences Program, Entebbe, Uganda.
Michael A EllerU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, United States.
Merlin L RobbU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, United States.
Ronald GrayDepartment of Epidemiology, Johns Hopkins University, Baltimore, United States.
Godfrey KigoziRakai Health Sciences Program, Entebbe, Uganda.
Oliver LaeyendeckerLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, United States.
Katrina A LythgoeMRC Centre for Outbreak Analysis and Modelling, Imperial College London, London, United Kingdom.
Gertrude NakigoziRakai Health Sciences Program, Entebbe, Uganda.
Thomas C QuinnLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, United States.
Steven J ReynoldsLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, United States.
Maria J WawerDepartment of Epidemiology, Johns Hopkins University, Baltimore, United States.
Christophe FraserMRC Centre for Outbreak Analysis and Modelling, Imperial College London, London, United Kingdom.

Funding

University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI Judith Tsui · 1988 to 2026
$104.9M
International Center for Excellence in Research (ICER) in Uganda: Impact of ARVsZIAAI001040 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI REYNOLDS, STEVEN · 2009 to 2025
$23.5M
TUBERCULOSIS INTERNATIONAL TRAINING AND RESEARCH PROGRAMD43TW000010 · FIC · JOHNS HOPKINS UNIVERSITY · PI BEYRER, CHRISTOPHER C. · 1988 to 2012
$19.8M
International Studies of the Acquired Immune Deficiency Syndrome (AIDS)ZIAAI000361 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI REDD, ANDREW · 2009 to 2025
$15.8M
Integrated bio-social models for HIV epidemiologyR01AI108490 · NIAID · UNIVERSITY OF WASHINGTON · PI GOODREAU, STEVEN M., HERBECK, JOSHUA T · 2014 to 2018
$3.4M
Revealing women's hidden role as critical components of HIV transmission networks in Rakai, Uganda: an interdisciplinary approachK01AI125086 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GRABOWSKI, MARY KATHRYN · 2016 to 2020
$638k
European Research Council 339251FIC NIH HHS D43 TW000010NIAID NIH HHS K01 AI125086NIAID NIH HHS P30 AI027757NIAID NIH HHS R01 AI108490
6 · The paper itself

Abstract

Evolutionary theory hypothesizes that intermediate virulence maximizes pathogen fitness as a result of a trade-off between virulence and transmission, but empirical evidence remains scarce. We bridge this gap using data from a large and long-standing HIV-1 prospective cohort, in Uganda. We use an epidemiological-evolutionary model parameterised with this data to derive evolutionary predictions based on analysis and detailed individual-based simulations. We robustly predict stabilising selection towards a low level of virulence, and rapid attenuation of the virus. Accordingly, set-point viral load, the most common measure of virulence, has declined in the last 20 years. Our model also predicts that subtype A is slowly outcompeting subtype D, with both subtypes becoming less virulent, as observed in the data. Reduction of set-point viral loads should have resulted in a 20% reduction in incidence, and a three years extension of untreated asymptomatic infection, increasing opportunities for timely treatment of infected individuals.

Indexed as

Biological EvolutionGenetic FitnessHIV-1HIV InfectionsHost-Pathogen InteractionsHumansModels, BiologicalUgandaViral Loadadaptationepidemiologyevolutionary biologygenomicsglobal healthquantitative geneticsselectiontransmission-virulence trade-offviral evolutionvirus

Identifiers

PMID27815945
PMCPMC5115872

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.